Iscartrelvir is an investigational new drug developed by the Westlake University for the treatment of COVID-19. It targets the SARS-CoV-2 3CL protease, which is crucial for the replication of the virus responsible for COVID-19.[1][2]
Clinical data | |
---|---|
Other names | WPV01; WU-04 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
PDB ligand | |
Chemical and physical data | |
Formula | C24H24BrN5O4 |
Molar mass | 526.391 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ Yang L, Wang Z (September 2023). "Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China". European Journal of Medicinal Chemistry. 257: 115503. doi:10.1016/j.ejmech.2023.115503. PMC 10193775. PMID 37229831.
- ^ Hou N, Shuai L, Zhang L, Xie X, Tang K, Zhu Y, et al. (February 2023). "Development of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 3CLpro". ACS Central Science. 9 (2): 217–227. doi:10.1021/acscentsci.2c01359. PMC 9885526. PMID 36844503.217-227&rft.date=2023-02&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885526#id-name=PMC&rft_id=info:pmid/36844503&rft_id=info:doi/10.1021/acscentsci.2c01359&rft.aulast=Hou&rft.aufirst=N&rft.au=Shuai, L&rft.au=Zhang, L&rft.au=Xie, X&rft.au=Tang, K&rft.au=Zhu, Y&rft.au=Yu, Y&rft.au=Zhang, W&rft.au=Tan, Q&rft.au=Zhong, G&rft.au=Wen, Z&rft.au=Wang, C&rft.au=He, X&rft.au=Huo, H&rft.au=Gao, H&rft.au=Xu, Y&rft.au=Xue, J&rft.au=Peng, C&rft.au=Zou, J&rft.au=Schindewolf, C&rft.au=Menachery, V&rft.au=Su, W&rft.au=Yuan, Y&rft.au=Shen, Z&rft.au=Zhang, R&rft.au=Yuan, S&rft.au=Yu, H&rft.au=Shi, PY&rft.au=Bu, Z&rft.au=Huang, J&rft.au=Hu, Q&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885526&rfr_id=info:sid/en.wikipedia.org:Iscartrelvir" class="Z3988">